Niraparib with Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: Phase II QUEST Study Results

被引：7

作者：

Chi, Kim N. ^{[1
]}

Fleshner, Neil ^{[2
]}

Chiuri, Vincenzo Emanuele ^{[3
]}

Van Bruwaene, Siska ^{[4
]}

Hafron, Jason ^{[5
]}

McNeel, Douglas G. ^{[6
]}

De Porre, Peter ^{[7
]}

Maul, Raymond Scott ^{[8
]}

Daksh, Mahesh ^{[9
]}

Zhong, Xiaogang ^{[10
]}

Mason, Gary E. ^{[11
]}

Tutrone, Ronald F. ^{[12
]}

机构：

[1] Univ British Columbia, BC Canc Vancouver Ctr, Vancouver, BC, Canada

[2] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] I Veris Delli Ponti Hosp, Lecce, Italy

[4] AZ Groeninge Hosp, Dept Urol, Kortrijk, Belgium

[5] Michigan Inst Urol, W Bloomfield, MI USA

[6] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[7] Janssen Res & Dev, Beerse, Belgium

[8] Janssen Res & Dev, Los Angeles, CA USA

[9] Janssen Res & Dev, Raritan, NJ USA

[10] Janssen Res & Dev, College Pk, MD USA

[11] Janssen Res & Dev, Spring House, PA USA

[12] Chesapeake Urol Res Assoc, Towson, MD USA

来源：

ONCOLOGIST | 2023年 / 28卷 / 05期

关键词：

castration-resistant prostate cancer; PARP inhibitor; homologous recombination repair; niraparib; abiraterone acetate;

D O I：

10.1093/oncolo/oyad008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations in patients with metastatic castration-resistant prostate cancer who were positive for homologous recombination repair gene alterations and had progressed on 1 prior line of novel androgen receptor-targeted therapy. Results from the combination of NIRA with abiraterone acetate plus prednisone, which disrupts androgen axis signaling through inhibition of CYP17, showed promising efficacy and a manageable safety profile in this patient population.

引用

页码：E309 / E312

页数：4

共 50 条

[41] Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Slovin, Susan F.
Knudsen, Karen
Halabi, Susan
de Leeuw, Renee
Shafi, Ayesha
Kang, Praneet
Wolf, Steven
Luo, Bin
Gopalan, Anuradha
Curley, Tracy
Fleming, Mark
Molina, Ana
Fernandez, Celina
Kelly, Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 5015 - +
[42] Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
Ferrero, Jean-Marc
Mahammedi, Hakim
Gravis, Gwenaelle
Roubaud, Guilhem
Beuzeboc, Philippe
Largillier, Remi
Borchiellini, Delphine
Linassier, Claude
Ebran, Nathalie
Pace-Loscos, Tanguy
Etienne-Grimaldi, Marie-Christine
Schiappa, Renaud
Gal, Jocelyn
Milano, Gerard
PHARMACEUTICS, 2023, 15 (02)
[43] A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone
Lin, Jianqing
Sama, Ashwin Reddy
Hoffman-Censits, Jean H.
Kennedy, Brooke
Kilpatrick, Deborah
Ye, Zhong
Yang, Hushan
Mu, Zhaomei
Leiby, Benjamin E.
Lewis, Nancy
Cristofanilli, Massimo
Kelly, William Kevin
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[44] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
Yang, Zhenyu
Ni, Yuchao
Zhao, Diwei
Zhang, Yijun
Wang, Jun
Jiang, Lijuan
Chen, Dong
Wu, Zhiming
Wang, Yanjun
He, Liru
Shi, Yanxia
Zhou, Fangjian
Zeng, Hao
Li, Yonghong
BMC CANCER, 2021, 21 (01)
[45] Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer
Emamekhoo, Hamid
Barata, Pedro C.
Edwin, Natasha C.
Woo, Kaitlin M.
Grivas, Petros
Garcia, Jorge A.
CLINICAL GENITOURINARY CANCER, 2018, 16 (06) : 429 - 436
[46] Corticosteroid switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients with biochemical progression on abiraterone acetate plus prednisone
Zhenyu Yang
Yuchao Ni
Diwei Zhao
Yijun Zhang
Jun Wang
Lijuan Jiang
Dong Chen
Zhiming Wu
Yanjun Wang
Liru He
Yanxia Shi
Fangjian Zhou
Hao Zeng
Yonghong Li
BMC Cancer, 21
[47] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
Romero-Laorden, Nuria
Lozano, Rebeca
Jayaram, Anuradha
Lopez-Campos, Fernando
Saez, Maria, I
Montesa, Alvaro
Gutierrez-Pecharoman, Ana
Villatoro, Rosa
Herrera, Bernardo
Correa, Raquel
Rosero, Adriana
Pacheco, Maria, I
Garces, Teresa
Cendon, Ylenia
Paz Nombela, Ma
Van de Poll, Floortje
Grau, Gala
Rivera, Leticia
Lopez, Pedro P.
Cruz, Juan-Jesus
Lorente, David
Attard, Gerhardt
Castro, Elena
Olmos, David
BRITISH JOURNAL OF CANCER, 2018, 119 (09) : 1052 - 1059
[48] Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
Freedland, Stephen J.
Li, Sophia
Pilon, Dominic
Bhak, Rachel H.
Narkhede, Sahil
Lefebvre, Patrick
Young-Xu, Yinong
CURRENT MEDICAL RESEARCH AND OPINION, 2021, 37 (04) : 635 - 642
[49] Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)
Nuria Romero-Laorden
Rebeca Lozano
Anuradha Jayaram
Fernando López-Campos
Maria I. Saez
Alvaro Montesa
Ana Gutierrez-Pecharoman
Rosa Villatoro
Bernardo Herrera
Raquel Correa
Adriana Rosero
María I. Pacheco
Teresa Garcés
Ylenia Cendón
Ma Paz Nombela
Floortje Van de Poll
Gala Grau
Leticia Rivera
Pedro P. López
Juan-Jesús Cruz
David Lorente
Gerhardt Attard
Elena Castro
David Olmos
British Journal of Cancer, 2018, 119 : 1052 - 1059
[50] A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer
McKay, Rana R.
Werner, Lillian
Jacobus, Susanna J.
Jones, Xandra
Mostaghel, Elahe A.
Marck, Brett T.
Choudhury, Atish D.
Pomerantz, Mark M.
Sweeney, Christopher J.
Slovin, Susan F.
Morris, Michael J.
Kantoff, Philip W.
Taplin, Mary-Ellen
CANCER, 2019, 125 (04) : 524 - 532

← 1 2 3 4 5 →